BEYİN KİTLELERİNDE NEOPLASTİK / NEOPLASTİK OLMAYAN VE YÜKSEK EVRE / DÜŞÜK EVRE AYRIMINDA MR SPEKTROSKOPİNİN YERİ

Abstract

Amaç: Bu çalışmanın amacı serebral lezyonların ayırıcı tanısında Manyetik Rezonans Spektroskopinin etkinliğini araştırmaktır. Yöntem: Serebral lezyonu olan 46 olgu Manyetik Rezonans Spektroskopi ile incelendi. Kolin, kreatin, Nasetil aspartat ve lipid-laktat pikleri değerlendirildi. Kırk altı olgunun 40'ına stereotaktik biopsi ya da operasyon uygulandı. Histopatolojik sonuçlar ile Manyetik Rezonans Spektroskopi sonuçları karşılaştırıldı. Bulgular: Lezyonların neoplastik/neoplastik olmayan ayrımında Kolin/N-asetil aspartat en yüksek duyarlılığa sahipti (%87.2) ve Kolin/Kreatin, Kolin/N-asetil aspartat, Kolin+Kreatin/N-asetil aspartat oranlarının özgüllük değerleri %100 olarak hesaplandı. Düşük/yüksek evre ayrımında Kolin/Kreatin en yüksek duyarlılığa sahipti (%95.7) ve Kolin/N-asetil aspartat, Kolin+Kreatin/N-asetil aspartat, lipid-laktat oranlarının özgüllüğü %100 olarak hesaplandı. Sonuç olarak Kolin/Kreatin oranının 2.2'den yüksek olması ve eşlik eden lipid-laktat pikinin neoplastik lezyonların düşük/yüksek evre ayrımında %100 (%82.2-100) duyarlılık ve %100 (%71.7-100) özgüllüğe sahip olduğu görüldü. Sonuç: Yüksek Kolin ve düşük N-asetil aspartat piklerinin lezyonların neoplastik/neoplastik olmayan ayrımında etkili olduğu görüldü. Neoplastik lezyonların yüksek/düşük evre ayrımında ise 2.2'den yüksek Kolin/Kreatin oranı ve eşlik eden lipid-laktat pikinin değerli bilgiler verdiği sonucuna varıldı.

Anahtar Kelimeler: Beyin neoplazmları, Manyetik rezonans görüntüleme, Manyetik rezonans spektroskopi, Stereotaktik biyopsi

Keywords

• -

References

1. Dowling C, Bollen AW, Noworolski SM, et al.
2. Preoperative proton MR spectroscopic imaging of brain
3. tumors: correlation with histopathologic analysis of
4. resection specimens specimens. AJNR Am J
5. Neuroradiol 2001; 22: 604–612.
6. Hourani R, Brant LJ, Rizk T, Weingart JD, Barker PB,
7. Horská A. Can proton MR spectroscopic and perfusion
8. imaging differentiate between neoplastic and

9. nonneoplastic brain lesions in adults? AJNR Am J
10. Neuroradiol 2008; 29:366-372.
11. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative
12. grading of gliomas by using metabolite quantification
13. with high-spatial-resolution proton MR spectroscopic
14. imaging. Radiology 2006; 238:958-969.
15. Bulakbasi N, Kocaoglu M, Ors F, Tayfun C, Ucoz T.
16. Combination of single-voxel proton MR spectroscopy
17. and apparent diffusion coefficient calculation in the
18. evaluation of common brain tumors. AJNR Am J
19. Neuroradiol 2003; 24:225-233.
20. Bernstein M, Parrent AG. Complications of CT-guided
21. stereotactic biopsy of intra-axial brain lesions. J
22. Neurosurg 1994; 81:165–168.
23. Field M, Witham TF, Flickinger JC, Kondziolka D,
24. Lunsford LD. Comprehensive assessment of
25. hemorrhage risks and outcomes after stereotactic brain
26. biopsy. J Neurosurg 2001; 94:545–551.
27. Kreth FW, Muacevic A, Medele R, Bise K, Meyer T,
28. Reulen HJ. The risk of haemorrhage after image guided
29. stereotactic biopsy of intra-axial brain tumours: a
30. prospective study. Acta Neurochir (Wien) 2001; 143:
31. –545.
32. Sawin PD, Hitchon PW, Follett KA, Torner JC.
33. Computed imaging-assisted stereotactic brain biopsy: a
34. risk analysis of 225 consecutive cases. Surg Neurol
35. ; 49:640–649.
36. Yu X, Liu Z, Tian Z, Li S, Huang H, et al. Stereotactic
37. biopsy for intracranial space-occupying lesions: clinical
38. analysis of 550 cases. Stereotact Funct Neurosurg 2000;
39. :103–108.
40. Law M, Yang S, Wang H, et al. Glioma grading:
41. sensitivity, specificity, and predictive values of
42. perfusion MR imaging and proton MR spectroscopic
43. imaging compared with conventional MR imaging.
44. AJNR Am J Neuroradiol 2003; 24:1989-1998.
45. Al-Okaili RN, Krejza J, Woo JH, Wolf RL, O'Rourke
46. DM, Judy KD, et al. Intraaxial brain masses: MR
47. imagingbased diagnostic strategy—initial experience.
48. Radiology 2007; 243:539–550.
49. García-Gómez JM, Luts J, Julià-Sapé M, et al.
50. Multiproject-multicenter evaluation of automatic brain
51. tumor classification by magnetic resonance
52. spectroscopy. MAGMA 2009; 22:5-18.
53. Lin AP, Ross BD. Short-echo time proton MR
54. spectroscopy in the presence of gadolinium. J Comput
55. Assist Tomogr 2001; 25:705-712.
56. Murphy PS, Dzik-Jurasz AS, Leach MO, Rowland IJ.
57. The effect of Gd-DTPA on T(1)-weighted choline signal
58. in human brain tumours. Magn Reson Imaging 2002;
59. :127-130.
60. Smith JK, Kwock L, Castillo M. Effects of contrast
61. material on single-volume proton MR spectroscopy.
62. AJNR Am J Neuroradiol 2000; 21:1084-1089.
63. Spampinato MV, Smith JK, Kwock L, et al. Cerebral
64. blood volume measurements and proton MR
65. spectroscopy in grading of oligodendroglial tumors. AJR
66. Am J Roentgenol 2007; 188:204-212.
67. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive
68. differentiation of tumors with use of localized H-1 MR
69. spectroscopy in vivo: initial experience in patients with
70. cerebral tumors. Radiology 1989; 172: 541–548.
71. Castillo M, Kwock L, Mukherji SK. Clinical
72. applications of MR spectroscopy. AJNR Am J
73. Neuroradiol 1996; 17:1–15.
74. Krouwer HG, Kim TA, Rand SD, et al. Single-voxel
75. proton MR spectroscopy of nonneoplastic brain lesions
76. suggestive of a neoplasm. AJNR Am J Neuroradiol
77. ; 19:1695–1703.
78. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK,
79. Chhabra DK. Characterization of intracranial mass
80. lesions with in vivo proton MR spectroscopy. AJNR Am
81. J Neuroradiol 1995; 16:1593–1603.
82. Segebarth CM, Baleriaux DF, Luyten PR, den Hollander
83. JA. Detection of metabolic heterogeneity of human
84. intracranial tumors in vivo by H-1 NMR spectroscopic
85. imaging. Magn Reson Med 1990; 13:62–76.
86. Rand SD, Prost R, Haughton V, et al. Accuracy of
87. single-voxel proton MR spectroscopy in distinguishing
88. neoplastic from nonneoplastic brain lesions. AJNR Am J
89. Neuroradiol 1997; 18:1695–1704.
90. Demaerel P, Johannik K, van Hecke P, et al. Localized
91. H NMR spectroscopy in fifty cases of newly diagnosed
92. intracranial tumors. J Comput Assist Tomogr 1991;
93. :67–76.
94. Herholz K, Heindel W, Luyten PR, et al. In vivo
95. imaging of glucoseconsumption and lactate
96. concentration in human gliomas. Ann Neurol 1992;
97. :319–327.
98. Ott D, Hennig J, Ernst T. Human brain tumors:
99. assessment with in vivo proton MR spectroscopy.
100. Radiology 1993; 186:745–752.
101. Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive
102. evaluation of malignancy of brain tumors with proton
103. MR spectroscopy. AJNR Am J Neuroradiol 1996;
104. :737-747.
105. Kugel H, Heindel W, Ernestus R-I, Bunke J, du Mensil
106. R, Friedmann G. Human brain tumors: spectral patterns
107. detected with localized H-1 MR spectroscopy.
108. Radiology 1992; 183:701–709.
109. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain
110. tumor metabolites with proton MR spectroscopic
111. imaging: clinical relevance. Radiology 1992; 185:675-
112. -
113. -
114. Marmara Medical Journal 2010;23(3); 326-338
115. Ozan Karatağ, et al.
116. Can magnetic resonance spectroscopy adequately differentiate neoplastic from non-neoplastic and low-grade from highgrade
117. lesions in brain masses?
118. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton
119. magnetic resonance spectroscopy of brain tumors: an in
120. vitro study. Neurosurgery 1994; 35:606–614.
121. Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel
122. proton brain spectroscopy exam (PROBE/SV) in
123. patients with primary brain tumors. AJR Am J
124. Roentgenol 1996; 167:201-209.
125. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD,
126. Dunn JF. Classification of biopsy-confirmed brain
127. tumors using single-voxel MR spectroscopy. AJNR Am
128. J Neuroradiol 1999; 20:117–123.
129. Moller-Hartmann W, Herminghaus S, Krings T, et al.
130. Clinical application of proton magnetic resonance
131. spectroscopy in the diagnosis of intracranial mass
132. lesions. Neuroradiology 2002; 44:371–381.
133. Kimura T, Sako K, Gotoh T, Tanaka K, Tanaka T. In
134. vivo singlevoxel proton MR spectroscopy in brain
135. lesions with ring-like enhancement. NMR Biomed 2001;
136. :339–349.
137. Poptani H, Gupta RK, Jain VK, Roy R, Pandey R.
138. Cystic intracranial mass lesions: possible role of in vivo
139. MR spectroscopy in its differential diagnosis. Magn
140. Reson Imaging 1995; 13:1019-1029.
141. Luyten PR, Marien AJ, Heindel W, , et al. Metabolic
142. imaging of patients with intracranial tumors: 1H MR
143. spectroscopic imaging and PET. Radiology 1990;
144. :791–799.
145. Martin AJ, Liu H, Hall WA, Truwit CL. Preliminary
146. assessment of turbo spectroscopic imaging for targeting
147. in brain biopsy. AJNR Am J Neuroradiol 2001; 22:959-
148. -
149. Bizzi A, Movsas B, Tedeschi G, et al. Response of nonHodgkin
150. lymphoma to radiation therapy: early and longterm
151. assessment with H-1 MR spectroscopic imaging.
152. Radiology 1995; 194:271-276.
153. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt
154. AW. High-grade gliomas and solitary metastases:
155. differentiation by using perfusion and proton
156. spectroscopic MR imaging. Radiology 2002; 222:715-
157. -
158. Bendszus M, Warmuth-Metz M, Klein R. MR
159. spectroscopy in gliomatosis cerebri. Am J Neuroradiol
160. ; 21:375–380.
161. Pyhtinen J. Proton MR spectroscopy in gliomatosis
162. cerebri. Neuroradiology 2000; 42:612–615.
163. Uysal E, Erturk M, Yildirim H, et al. Multivoxel
164. magnetic resonance spectroscopy in gliomatosis cerebri.
165. Acta Radiol 2005; 46:621-624.
166. Garg M, Gupta RK, Husain M, et al. Brain abscesses:
167. etiologic categorization with in vivo proton MR
168. spectroscopy. Radiology 2004; 230:519-527.
169. Kim DG, Choe WJ, Chang KH, et al. In vivo proton
170. magnetic resonance spectroscopy of central
171. neurocytomas. Neurosurgery 2000; 46:329-334.
172. Lee DY, Chung CK, Hwang YS, et al.
173. Dysembryoplastic neuroepithelial tumor: radiological
174. findings (including PET, SPECT, and MRS) and
175. surgical strategy. J Neurooncol 2000; 47:167–174.
176. Sener RN. Neuro-Behcet's disease: diffusion MR
177. imaging and proton MR spectroscopy. AJNR Am J
178. Neuroradiol 2003; 24:1612-1614.
179. Baysal T, Ozisik HI, Karlidag R, et al. Proton MRS in
180. Behcet’s disease with and without neurological findings.
181. Neuroradiol 2003; 45:860-864.
182. Appenzeller S, Li LM, Costallat LT, Cendes F.
183. Neurometabolic changes in normal white matter may
184. predict appearance of hyperintense lesions in systemic
185. lupus erythematosus. Lupus 2007; 16:963-971.